| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/29/2004 | US20040019105 Compounds with stabilized S-nitrosyl group and a free alcohol or a free thiol; nitric oxide (no) releasing; bacteristats |
| 01/29/2004 | US20040019103 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof |
| 01/29/2004 | US20040019102 Administering a thiuram disulfide and a heavy metal ion; activated transcription factor/adenosine cyclic phosphate response element binding protein (atf/creb) |
| 01/29/2004 | US20040019101 Methods of treating gastrointestinary and genitourinary pain disorders |
| 01/29/2004 | US20040019100 HMG CoA-reductase inhibitors |
| 01/29/2004 | US20040019099 Treating inflammatory diseases, allergic conditions and central nervous system disorders |
| 01/29/2004 | US20040019096 Matrix formulation containing an organic acid; hypotensive agents; congestive heart failure and angina treatments |
| 01/29/2004 | US20040019095 N, N'-dimethylated N-confused porphyrins |
| 01/29/2004 | US20040019094 N-imine guanidine compounds; treatment of obesity, anorexia, inflammation and mental disorders |
| 01/29/2004 | US20040019093 Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them |
| 01/29/2004 | US20040019091 Cholecystokinin receptor agonists; antiobesity agents |
| 01/29/2004 | US20040019090 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents |
| 01/29/2004 | US20040019089 Multidrug resistant cell inhibitors; anticancer agents |
| 01/29/2004 | US20040019088 Use of Epothilones in the treatment of brain diseases associated with proliferative processes |
| 01/29/2004 | US20040019086 Aminediols for the treatment of Alzheimer's disease |
| 01/29/2004 | US20040019085 Ureido-substituted aniline compounds useful as serine protease inhibitors |
| 01/29/2004 | US20040019084 Nitric oxide synthase inhibitors; antioxidant regenerants |
| 01/29/2004 | US20040019083 Amino acid derivatives; antineoplastic agents |
| 01/29/2004 | US20040019082 Reversible infertility in male mice following oral administration of alkylated imino sugars: a non-hormonal approach to male contraception |
| 01/29/2004 | US20040019081 2, 6-disubstituted piperidines as modulators of nicotinic acetylcholine receptor mediated neurotransmitter release, uptake and storage |
| 01/29/2004 | US20040019080 Prevention and treatment of migraine and other recurrent headaches using leukotriene LTD4 receptor blocker drugs |
| 01/29/2004 | US20040019079 Beta3-Adrenoreceptor agonists, agonist compositions and methods of using |
| 01/29/2004 | US20040019078 Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
| 01/29/2004 | US20040019077 Heterocyclic imines such as N1-(8-sulfonamide-5-isoquinoline)-N2-(3,3-diphenyl-2-propenyl) -ethylenediamine, used for prophylaxis and diagnosis of cancers, diabetes, cardiovascular and nervous system disorders, autoimmune diseases or obesity |
| 01/29/2004 | US20040019075 New formulation for the parenteral application of crobenetine |
| 01/29/2004 | US20040019073 Mixtures of di-2-thienylglycolates, water, buffers, preservatives and stabilizer agents, administered for prophylaxis of respiratory system disorders such as asthma or chronic obstructive pulmonary disease |
| 01/29/2004 | US20040019072 Dimer-selective RXR modulators and methods for their use |
| 01/29/2004 | US20040019071 Preferential opiate receptors, used as analgesics, antitussive agents, immunosuppressants or neuroprotectants; side effect reduction |
| 01/29/2004 | US20040019070 Nitrogen compounds used as opiate receptor agonists or antagonists, for prophylaxis of drug abuse, cardiovascular, respiratory system, gastrointestinal disorders, as analgesics, antitussives or immunosuppressants |
| 01/29/2004 | US20040019068 Nitrogen compounds such as 2-(5-formylamino-6-oxo-2-phenyl-1,6 -dihydropyrimidin-1-yl)-N-(2,3-dioxo-1-phenylmethyl-6-(2 -pyridyloxy))hexylacetamide used for prophylaxis cardiovascular disorders; restenosis |
| 01/29/2004 | US20040019066 Methionine salvage pathway in bacillus |
| 01/29/2004 | US20040019065 Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use |
| 01/29/2004 | US20040019064 Pyridopyrimidine derivatives as 5-HT6 antagonists |
| 01/29/2004 | US20040019063 Nitrogen compounds such as 4-(7-Hydroxy-1,3-dioxo-tetrahydro-pyrrolo(1,2-c)imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile, used for prophylaxis of muscular disorders; aging |
| 01/29/2004 | US20040019062 Parasiticidal formulation for animals |
| 01/29/2004 | US20040019060 Drugs such as 9-(3,5-dimethyl-1-piperazinyl)propyl)carbazole, used for modulating endothelial cell proliferation |
| 01/29/2004 | US20040019059 Drugs such as N-(4-benzoylphenyl)-4,5-dihydro-3-(3-pyridinyl)-5-isoxazolecarboxamide, used as antiinflammatory or antiarthritic agents |
| 01/29/2004 | US20040019058 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 01/29/2004 | US20040019057 Imidazo-pyrazine derivatives as ligands for gaba receptors |
| 01/29/2004 | US20040019056 Anititumoral analogs of et-743 |
| 01/29/2004 | US20040019055 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/29/2004 | US20040019054 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/29/2004 | US20040019053 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| 01/29/2004 | US20040019052 5-(2,3-Difluorophenyl)-1H-pyrazolo(3,4-c)pyridazin-3-ylamine, e.g.; an enzyme inhibitor of GSK-3, a serine/threonine protein kinase; neuroprotectants in treatment of acute stroke, neurotraumatic injuries and diabetic conditions |
| 01/29/2004 | US20040019051 Eating disorders of a disturbed or impaired fundus such as dyspepsia, early satiety, bloating and anorexia; e.g.,1-(1-((2,3-dihydro(1,4)dioxino(2,3-b)pyridin-3-yl)methyl) -4- piperidinyl)-2-imidazolidinone |
| 01/29/2004 | US20040019049 Substituted quinazolinone compounds |
| 01/29/2004 | US20040019048 Imidazo(4,5-c)quinoline and the 6,7,8,9-tetrahydro derivative having urea, thiourea, acylurea or sulfonylurea at the 1-position as immune response modifiers; biosynthesis of cytokines; viricides; antitumor, -carcinogenic agents |
| 01/29/2004 | US20040019047 E.g., 5-bromo-2-(4-chloroanilino)-4-(2,4,6-trimethylphenoxy) pyridine-N-oxide; administering along with an HIV reverse transcriptase inhibitors (polymerase), HIV protease inhibitors, fusion inhibitors or CCR-5; kits |
| 01/29/2004 | US20040019046 Phenylacetamido-pyrazole derivatives and their use as antitumor agents |
| 01/29/2004 | US20040019045 Pyrazole compounds as anti-inflammatory and analgesic agents |
| 01/29/2004 | US20040019044 Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals |
| 01/29/2004 | US20040019041 Method for the production of imidazo-(1,2-C)(2,3)-benzodiazepines and intermediates in the production thereof |
| 01/29/2004 | US20040019040 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| 01/29/2004 | US20040019038 Compounds useful as anti-inflammatory agents |
| 01/29/2004 | US20040019037 E.g.,((5-(2,4-Diaminopyrimidin-6-yl)pentanoyl)-(N-methyl)amino )-3-(6-meth-oxypyridin-3-yl)-propanoic acid, inhibition of bone resorption, restenosis, angiogenesis inhibitors, antiarthritic, -tumor, -carcinogenic agents; antidiabetic |
| 01/29/2004 | US20040019036 Treating a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia; able to induce or to improve hematologic response and/or cytogenetic response and, eventually, survival, with a mild non-hematologic toxicity |
| 01/29/2004 | US20040019035 3-(5,6,7,8-Tetrahydro-(1,8)naphthyridin-2-yl)-ethoxy)-11H-di-b enzo(1,4)oxazepin-10-yl)-acetic acid; inhibiting bone resorption; vascular restenosis; osteoporosis; angiogenesis inhibitors; diabetic retinopathy; anticarcinogenic agents |
| 01/29/2004 | US20040019034 Pyrrolotriazolopyrimidinone derivatives |
| 01/29/2004 | US20040019032 Photodynamic therapy to treat for retinal macular edema (ME) that's more effective and less damaging to tissue surrounding an edematous lesion than laser photocoagulation; ME resulting from diabetes or central or branch retinal vein occulsion |
| 01/29/2004 | US20040019031 Nitrogen-containing macrocyclic compounds modulating intra-and extracellular levels of oxidants such as superoxide radicals, hydrogen peroxide and peroxynitrite radicals |
| 01/29/2004 | US20040019030 Administering to a patient suffering from psychological disorder, an antipsychotic agent in combination with a chromium picolinate, for minimizing side effects in a patient taking an atypical antipsychotic agent |
| 01/29/2004 | US20040019029 Manzamines for treatment of drug resistant infection |
| 01/29/2004 | US20040019028 Administering to a patient with mild cognitive impairment, a specific glucocorticoid receptor antagonist such as mifepristone to improve performance on a paragraph recall test |
| 01/29/2004 | US20040019027 Method of treating cerebrotendinous xanthomatosis |
| 01/29/2004 | US20040019026 Compounds useful for treating hypertriglyceridemia |
| 01/29/2004 | US20040019025 Formulations of (R,R)-formoterol fumarate (adrenoreceptor agonist) and rofleponide (antiinflammatory corticoid); respiratory system disorders; asthma; chronic obstructive pulmonary disease; respiratory tract infections |
| 01/29/2004 | US20040019024 Administering to a patient a vitamin D derivative antagonist to treat Paget's disease of bone |
| 01/29/2004 | US20040019023 Administering 9,10-secopregna-5,7,10(19),16- tetraene derivative to a patient for treating skin diseases such as psoriasis |
| 01/29/2004 | US20040019022 Administering to a patient for preventing dysfunction, damage or injury of cells or tissues of a organ result from diseases, infections, or conditions which result in the formation of reactive oxygen species |
| 01/29/2004 | US20040019020 Phosphinyl phosphonate compounds treat hyperphosphatemia, chronic renal failure, disorders of phosphate metabolism, hyperparathyroidism, uremic bone disease, soft tissue calcification or osteoporosis |
| 01/29/2004 | US20040019016 Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor |
| 01/29/2004 | US20040019015 Administering an effective amount of a protein tyrosine kinase inhibitor (containing first and second module) to the patient to protect against or to treat hearing loss |
| 01/29/2004 | US20040019012 A therapeutic drug suitable for topical administration to an eye, containing an antibiotic for gram-positive bacterial infection, a cyclodextrin compound to maintain drug in solution and cetylpyridium chloride |
| 01/29/2004 | US20040019011 Treatment of conitions and disease |
| 01/29/2004 | US20040019010 Carrageenan viscoelastics for ocular surgery |
| 01/29/2004 | US20040019008 Compositions and processes using siRNA, amphipathic compounds and polycations |
| 01/29/2004 | US20040019007 Intravascular delivery of non-viral nucleic acid |
| 01/29/2004 | US20040019002 Gene repair involving the induction of double-stranded DNA cleavage at a chromosomal target site |
| 01/29/2004 | US20040018998 Antidiabetic agents; hypoglycemic agents; dietetics |
| 01/29/2004 | US20040018995 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; antidiabetic agents |
| 01/29/2004 | US20040018994 3-Descladinosyl-6-O-carbamoyl and 6-O-carbonoyl macrolide antibacterial agents |
| 01/29/2004 | US20040018991 Topical treatment for mastalgia |
| 01/29/2004 | US20040018990 Oral administering glucosidase inhibitor and glucose and, or honey; block adsorption of carbohydrates; controlling blood sugar |
| 01/29/2004 | US20040018989 Pulmonary delivery for levodopa |
| 01/29/2004 | US20040018987 Redox therapy for tumors |
| 01/29/2004 | US20040018983 Binding to zinc finger domain protein |
| 01/29/2004 | US20040018972 Autoimmune diseases; antiallergens; rheumatic diseases; antiinflammatory agents |
| 01/29/2004 | US20040018969 Genetic engineering; central nervous system disorders |
| 01/29/2004 | US20040018968 Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
| 01/29/2004 | US20040018966 Methods and compositions for use in perfusion applications |
| 01/29/2004 | US20040018963 O-derivatized nocathiacin derivatives |
| 01/29/2004 | US20040018962 Drug delivery vehicles |
| 01/29/2004 | US20040018960 Antitumor agents; autoimmune diseases; antiarthritic agents; restenosis |
| 01/29/2004 | US20040018959 System and methods of lipid removal from the body |
| 01/29/2004 | US20040018958 Methods for therapy of radiation cutaneous syndrome |
| 01/29/2004 | US20040018956 Aporphine esters and their use in therapy |
| 01/29/2004 | US20040018605 Anticancer agents; autoimmune diseases; central nervous system disorders; polymerase chain reactions |
| 01/29/2004 | US20040018598 Chemical intermediate for discodermolide, epothilone |
| 01/29/2004 | US20040018571 PSCA: prostate stem cell antigen and uses thereof |
| 01/29/2004 | US20040018546 Using labeled fluid; medical diagnosis |